All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @spvdy2 on TikTok · 116s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @spvdy2's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Well, we five CGC no DAC IPA IGF one I took a couple days off of using them because I had to travel
  2. 0:08One thing I noticed right when I went back on was how much of those spike your hunger
  3. 0:14I actually recently had to start using terrors and reda. Well now I'm fully on reda
  4. 0:19To counter the hunger of how much it spiked by Epam Reline
  5. 0:24So so far I'm about 205 at 6 to I'm relatively 15 to 18%
  6. 0:32Which is not much better than I was at a hundred and eighty three pounds
  7. 0:36Most of my weight gain is going to be watering glycogen, but there is some serious gains in there my arms at peak cut
  8. 0:42We're barely 13 inches now I'm measuring about 14.25 with no
  9. 0:47With no pump sorry
  10. 0:50I currently am dropping IGF one to test if my gains I got arm just water and glycogen due to better
  11. 0:57nutrient partitioning or if it's serious gains
  12. 1:02But so far it has been a week off of IGF one and my arms do still look very very full
  13. 1:07But yeah, I was off of any GOP and off of CGC no DAC and I was eating under 2k calories a day
  14. 1:14Just fine like obviously I'm dieting and trying and getting 20k steps and working out
  15. 1:19But I was able to do it fine the second I started to see they see no DAC and Epah again. I was eating five six
  16. 1:25Hey every day and then it takes about three megs of reda to suppress the appetite the blow
  17. 1:33Everything just to balance it out to where I'm eating about two doubt
  18. 1:372200 to 3,000 a day
  19. 1:40But since my days levels are higher
  20. 1:43I'm burning more fat. So I look better
  21. 1:46But yeah, that is an update
  22. 1:48I will be updating guys to see if my arms shrink after using IGF one or if they actually did anything but yeah, I'm excited

@spvdy2's peptide claims about CJC and ipamorelin, fact-checked

spvdy backup

TikTok creator

5.8K viewsWatch on TikTok

Quick answer

The creator is self-administering a stack of CJC-1295 no-DAC (a GHRH analogue), ipamorelin (a GHRP/ghrelin mimetic), and IGF-1 while using a GLP-1 receptor agonist to manage appetite overstimulation from the stack. This represents an unsupervised multi-axis intervention targeting the GH/IGF-1 axis simultaneously with GLP-1 signaling, a combination that has no established safety or dosing data in healthy adults outside clinical trial settings. Reported body composition changes over the cycle period are consistent with glycogen supercompensation and water retention secondary to elevated IGF-1 activity rather than confirmed lean mass accrual.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @spvdy2's peptide claims about CJC and ipamorelin, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@spvdy2's peptide claims about CJC and ipamorelin, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this ipamorelin video claims cluster

Best for searchers comparing ipamorelin claims with CJC-1295, sermorelin, and growth-hormone peptide evidence.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@spvdy2's peptide claims about CJC and ipamorelin, fact-checked" from spvdy backup. We read the clip as a Peptide social video fact-checks claim about Ipamorelin, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is self-administering a stack of CJC-1295 no-DAC (a GHRH analogue), ipamorelin (a GHRP/ghrelin mimetic), and IGF-1 while using a GLP-1 receptor agonist to manage appetite overstimulation from the stack.

The reason this review is not generic is the source wording and the canonical claim label "peptides cjc peptide igf1 ipamorelin grey gh hgh." In this clip, the useful excerpt is: "Well, we five CGC no DAC IPA IGF one I took a couple days off of using them because I had to travel One thing I noticed right when I went back on was how much of those spike your hunger I actually recently had to start using terrors and..." That wording changes the review because it points to Ipamorelin evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. Ipamorelin decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Ghrelin-pathway activation from GH secretagogues is a documented mechanism: Sigalos and Pastuszak (2018) confirmed appetite stimulation as a consistent side effect class, supporting the creator's hunger observation.
People who land here are usually comparing the Ipamorelin claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Ipamorelin guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is self-administering a stack of CJC-1295 no-DAC (a GHRH analogue), ipamorelin (a GHRP/ghrelin mimetic), and IGF-1 while using a GLP-1 receptor agonist to manage appetite overstimulation from the stack.

FormBlends verdict

Ipamorelin evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is self-administering a stack of CJC-1295 no-DAC (a GHRH analogue), ipamorelin (a GHRP/ghrelin mimetic), and IGF-1 while using a GLP-1 receptor agonist to manage appetite overstimulation from the stack. This represents an unsupervised multi-axis intervention targeting the GH/IGF-1 axis simultaneously with GLP-1 signaling, a combination that has no established safety or dosing data in healthy adults outside clinical trial settings. Reported body composition changes over the cycle period are consistent with glycogen supercompensation and water retention secondary to elevated IGF-1 activity rather than confirmed lean mass accrual.
  • CJC-1295 and ipamorelin are not FDA-approved for performance enhancement or body recomposition and are classified as research compounds with variable purity in unregulated supply chains.
  • Ghrelin-pathway activation from GH secretagogues is a documented mechanism: Sigalos and Pastuszak (2018) confirmed appetite stimulation as a consistent side effect class, supporting the creator's hunger observation.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • CJC-1295 and ipamorelin are not FDA-approved for performance enhancement or body recomposition and are classified as research compounds with variable purity in unregulated supply chains.
  • Ghrelin-pathway activation from GH secretagogues is a documented mechanism: Sigalos and Pastuszak (2018) confirmed appetite stimulation as a consistent side effect class, supporting the creator's hunger observation.
  • Rapid arm size increases over a short peptide cycle are more consistent with IGF-1-driven glycogen and water retention via PI3K/Akt signaling than with new contractile tissue, as Clemmons (2009, Nature Reviews Drug Discovery) explains.
  • Renehan et al. (2004, The Lancet) identified associations between elevated circulating IGF-1 and cancer risk in large observational data, a finding that has not been overturned and is relevant to long-term unsupervised IGF-1 use.
  • Self-administering a GLP-1 agonist at doses above established clinical ceilings to manage side effects from a separate unsupervised peptide stack compounds both the regulatory and physiological risks involved.
  • No compounded peptide is equivalent to an FDA-approved pharmaceutical: purity, concentration, and sterility standards differ significantly and affect both safety and outcomes.
  • Peptide therapy involving the GH/IGF-1 axis requires baseline and follow-up bloodwork including IGF-1 levels, HbA1c, and a lipid panel, none of which are mentioned in this self-reported protocol.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @spvdy2 actually say?

The creator described running a stack of CJC-1295 no-DAC, ipamorelin, and IGF-1, then briefly stopping during travel and noticing how quickly hunger spiked when they resumed. They report going from 183 lbs to 205 lbs at 6'2", estimating 15-18% body fat, with arm measurements jumping from "barely 13 inches" to "14.25 inches" without a pump. They're now testing whether dropping IGF-1 causes arm size to shrink, which would indicate the gains were mostly water and glycogen rather than contractile tissue. They're also using a GLP-1 receptor agonist (referred to as "reda" and "semaglutide" context strongly implied) at roughly 3 mg to counter the appetite stimulation from their peptide stack.

Does the science back this up?

The hunger-amplifying effect of GHRH/GHRP combinations is real and documented. The arm-size claim is harder to evaluate without a controlled baseline.

CJC-1295 stimulates growth hormone-releasing hormone (GHRH) receptor activity, and ipamorelin acts as a ghrelin mimetic at the GHS-R1a receptor. Both pathways are known to stimulate ghrelin-adjacent hunger signaling. Sigalos and Pastuszak (2018, Sexual Medicine Reviews) reviewed GH secretagogues and confirmed appetite stimulation as a consistent side effect. Whether this reaches the level the creator describes, needing a GLP-1 agonist to compensate, is plausible but highly individual. On arm size: a 1.25-inch increase in arm circumference over a peptide cycle is aggressive. Most of that change, as the creator themselves admits, is likely intramuscular glycogen storage and water retention from elevated IGF-1 activity, not myofibrillar hypertrophy. That self-awareness is actually commendable.

What did they get wrong (or right)?

They got the mechanism directionally correct but oversimplified. The IGF-1 drop-off test is actually reasonable science thinking.

Where they went sideways: framing this as a clean muscle-building outcome. IGF-1 drives glucose uptake and glycogen synthesis in muscle cells via PI3K/Akt signaling (Clemmons, 2009, Nature Reviews Drug Discovery), so fuller-looking muscles after IGF-1 use is largely a nutrient partitioning and glycogen story, not new fiber growth in a matter of weeks. The creator seems to understand this at the end, which is worth crediting. Where they got it right: the self-experiment logic of removing IGF-1 to isolate its effect is actually a reasonable n=1 washout approach. And the acknowledgment that eating 5-6 meals a day "just fine" once back on peptides is a textbook description of ghrelin-pathway activation. The semaglutide counter-measure is a real clinical tool, though using 3 mg to offset peptide-induced hunger is not a standard protocol and carries its own risk profile.

What should you actually know?

These peptides are not FDA-approved for performance use, and the stack described carries real physiological and regulatory risks that the video glosses over entirely.

CJC-1295 and ipamorelin are research compounds. They are not approved by the FDA for bodybuilding, fat loss, or general "optimization." Compounded versions vary in purity and potency. The combination with an injectable GLP-1 agonist at the doses implied here adds cardiovascular and gastrointestinal risks that a 5.8K-view TikTok doesn't have the space to address. Elevated IGF-1 over time is also not consequence-free. Renehan et al. (2004, The Lancet) found associations between circulating IGF-1 levels and cancer risk in observational data, a finding that hasn't gone away in 20 years of follow-up literature. None of this means these compounds have zero legitimate clinical use. But self-dosing a multi-peptide stack plus a GLP-1 agent based on scale weight and a tape measure is not the same as supervised therapy.

The bottom line

The creator is doing something more thoughtful than most peptide content: they're actively testing their own claims. But the video still normalizes a complex, unmonitored hormonal intervention.

The hunger amplification claim is scientifically plausible. The arm size gains are almost certainly mostly glycogen and water, which the creator half-admits. The broader framing of this stack as a reliable body recomposition tool skips over the regulatory status of these compounds, the purity and dosing variability in unregulated supply chains, and the longer-term hormonal risks of sustained GH axis stimulation. If you're considering peptide therapy, that conversation starts with a licensed provider who can actually run bloodwork, not a TikTok update at 205 lbs.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

spvdy backup · TikTok creator

5.8K views on this video

#cjc #peptide #igf1 #ipamorelin #grey #gh #hgh

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about cjc-1295?

CJC-1295 and ipamorelin are not FDA-approved for performance enhancement or body recomposition and are classified as research compounds with variable purity in unregulated supply chains.

What does the video say about ghrelin-pathway activation from gh secretagogues?

Ghrelin-pathway activation from GH secretagogues is a documented mechanism: Sigalos and Pastuszak (2018) confirmed appetite stimulation as a consistent side effect class, supporting the creator's hunger observation.

What does the video say about rapid arm size increases over a short peptide cycle?

Rapid arm size increases over a short peptide cycle are more consistent with IGF-1-driven glycogen and water retention via PI3K/Akt signaling than with new contractile tissue, as Clemmons (2009, Nature Reviews Drug Discovery) explains.

What does the video say about renehan et al. (2004, the lancet) identified associations between elevated?

Renehan et al. (2004, The Lancet) identified associations between elevated circulating IGF-1 and cancer risk in large observational data, a finding that has not been overturned and is relevant to long-term unsupervised IGF-1 use.

What does the video say about self-administering a glp-1 agonist at doses above established clinical ceilings?

Self-administering a GLP-1 agonist at doses above established clinical ceilings to manage side effects from a separate unsupervised peptide stack compounds both the regulatory and physiological risks involved.

What does the video say about no compounded peptide?

No compounded peptide is equivalent to an FDA-approved pharmaceutical: purity, concentration, and sterility standards differ significantly and affect both safety and outcomes.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by spvdy backup, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.